Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury

Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antith...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:CNS Neurosci Ther
Auteurs principaux: Lee, Jeong Hyun, Park, So Youn, Shin, Hwa Kyoung, Kim, Chi Dae, Lee, Won Suk, Hong, Ki Whan
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Inc 2008
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494013/
https://ncbi.nlm.nih.gov/pubmed/18482026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2008.00042.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires